Fatal bilateral intracerebral hemorrhages occurred shortly after intravenous tenecteplase in a 72-year-old donanemab-treated man, heterozygous for APOE4, who presented with headache and slurred speech 7 days after a fifth dose in the long-term addendum [71]. Here, APOE is linked to hemorrhage.